Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.
- Revenue
- +3.07%
- EPS
- −13.5%
- Free cash flow
- +29.8%
- Total debt
- −7.50%
Quarter to September 2026, against a year earlier
Follow ZBH
Alert me
Zimmer Biomet Holdings, Inc. (ZBH) P/E ratio
As of 5 November 2026, Zimmer Biomet Holdings, Inc. (ZBH) trades at a P/E ratio of 26.9×. Over the past ten years it has ranged from 0.0× (March 2021) to 716× (September 2020); the current reading is higher than 47% of that period. That is above the Medical Devices industry median of 25.6× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 25.2× | 6.11% |
| FY2024 | 23.7× | (3.99%) |
| FY2023 | 24.7× | (78.63%) |
| FY2022 | 116× | 79.20% |
| FY2021 | 64.6× | — |
| FY2020 | 0.0× | — |
| FY2019 | 26.6× | — |
| FY2018 | 0.0× | — |
| FY2017 | 13.4× | (80.34%) |
| FY2016 | 68.0× | (37.90%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 22.4× | 7.27% |
| Jun 2026 | 20.8× | (10.78%) |
| Mar 2026 | 23.4× | (7.24%) |
| Dec 2025 | 25.2× | 3.82% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GKOS Glaukos Corporation compare | n/m |
| GMED Globus Medical, Inc. compare | 19.5× |
| PODD Insulet Corporation compare | 25.2× |
| PHG Koninklijke Philips N.V. compare | 25.8× |
| ZBH Zimmer Biomet Holdings, Inc. | 26.9× |
| STE STERIS plc compare | 30.0× |
| DXCM DexCom, Inc. compare | 32.6× |
| SNN Smith & Nephew SNATS, Inc. compare | 38.9× |
| PEN Penumbra, Inc. compare | 80.3× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on ZBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement